Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 61-70 of 406 for multiple

Edit search filters
  1. A Study To Evaluate CC-98633 To Treat Subjects With Relapsed And/or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Study Of ORIC-533 In Relapsed Or Refractory Multiple Myeloma

    Rochester, MN

  3. A Study Comparing Anitocabtagene Autoleucel To Standard Of Care Therapy In Participants With Relapsed/ Refractory Multiple Myeloma (IMMagine-3)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Bortezomib Or Carfilzomib With Lenalidomide And Dexamethasone In Treating Patients With Newly Diagnosed Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study To Compare The Effectiveness And Safety Of Bb2121 Versus Standard Regimens In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study In Subjects With Relapsed And Refractory Multiple Myeloma Receiving Carfilzomib In Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)

    Scottsdale/Phoenix, AZ

  8. A Study To Evaluate The Effectiveness And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With Clinical High-Risk Multiple Myeloma

    Scottsdale/Phoenix, AZ

  9. Iberdomide, Daratumumab, Bortezomib, And Dexamethasone For Treatment Of Newly Diagnosed Multiple Myeloma, IDEAL Study

    Rochester, MN

  10. A Study Of TNB-383B In Subjects With Relapsed Or Refractory Multiple Myeloma

    Rochester, MN

.

Mayo Clinic Footer